Salary, Integrity and Selection of a New Chair for California’s $12 Billion Cell and Gene Therapy Enterprise
By David Jensen,
The California Stem Cell Report
| 05. 20. 2022
Photo by Giorgio Trovato on Unsplash
The directors of the $12 billion California stem cell agency are looking for a new chair who is both decisive and collaborative, passionate and inclusive. But at the top of the wish list is a person who is a pillar of integrity.
At least that is what a survey of the 35 board members showed today. The results were released this afternoon, less than one business day before the directors’ Governance Subcommittee takes up the matter of compensation and qualifications for the new chair.
The post carries a salary range that currently tops out at $566,500 annually. But that could be boosted by the directors of the California Institute for Regenerative Medicine (CIRM), as the agency is officially known. Also figuring into the salary is whether the post should be a full-time job.
The new chair will oversee CIRM during the next decade or so, a period in which its results are likely to determine whether it lives or dies. Depending on its pace of spending, the agency will run out of cash...
Related Articles
By Katie Hunt, CNN | 07.30.2025
Scientists are exploring ways to mimic the origins of human life without two fundamental components: sperm and egg.
They are coaxing clusters of stem cells – programmable cells that can transform into many different specialized cell types – to form...
By Ewen Callaway, Nature | 08.04.2025
For months, researchers in a laboratory in Dallas, Texas, worked in secrecy, culturing grey-wolf blood cells and altering the DNA within. The scientists then plucked nuclei from these gene-edited cells and injected them into egg cells from a domestic dog ...
By Kristel Tjandra, Genetic Engineering & Biotechnology News | 07.30.2025
CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on various fronts. But getting CRISPR experiments right in the lab isn’t simple...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...